文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

伤寒疫苗引入的证据生成:全球疾病负担估计与人类挑战试验的考量

Generating the Evidence for Typhoid Vaccine Introduction: Considerations for Global Disease Burden Estimates and Vaccine Testing Through Human Challenge.
PubMed 文献 · Clin Infect Dis · 2019-01-01

文章讨论了利用水源风险因素等 extrapolation 方法提高负担估计精度,并指出ViPS和Ty21a疫苗虽获WHO推荐但接种极少,而人类挑战模型加速了新型ViPS-破伤风类毒素结合疫苗的效力评估。

要点

  • 现有负担数据来自少量血培养监测研究,多限于人口密集城市中心,全球数字精度不足。
  • ViPS和Ty21a疫苗获WHO推荐已10年,但接种和引入极少。

核心结论

  • 更准确的疾病负担估计和人类挑战模型显示的疫苗效力使伤寒控制成为可能,尤其应对抗菌药物耐药问题。

研究设计与样本

  • 本文为综述,基于血培养监测研究等现有数据讨论伤寒负担估计方法与疫苗测试策略。

主要发现

  • 负担估计数据主要来自少量血培养监测研究,多限于人口密集城市中心。
  • ViPS和Ty21a疫苗获WHO推荐用于高负担国家已10年,其中一种ViPS疫苗获WHO预认证,但接种极少。
  • 人类挑战模型加速了新型ViPS-破伤风类毒素蛋白结合疫苗的测试,在大型现场试验前提供效力估计。

关键数值与推荐

  • WHO推荐ViPS和Ty21a疫苗用于高负担国家已10年,一种ViPS疫苗获WHO预认证。

临床怎么用

  • 应利用改进的负担估计方法和人类挑战模型证据推动伤寒疫苗在高负担国家的引入。

局限性

  • 负担数据受限于少量血培养监测研究,多来自城市中心,全球数字精度不足。
  • 疫苗虽获推荐但接种极少,实际影响有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Typhoid fever has had a major impact on human populations, with the causative pathogen Salmonella enterica serovar Typhi implicated in many outbreaks through history. The current burden of disease is estimated at 11-18 million infections annually, with the majority of infections located in Africa and South Asia. Data that have been used to estimate burden are limited to a small number of blood-culture surveillance studies, largely from densely populated urban centers. Extrapolating these data to estimate disease burden within and across countries highlights the lack of precision in global figures. A number of approaches have been developed, characterizing different geographical areas by water-based risk factors for typhoid infection or broader measures of health and development to more accurately extrapolate incidence. Recognition of the substantial disease burden is essential for policy-makers considering vaccine introduction. Typhoid vaccines have been in development for >100 years. The Vi polysaccharide (ViPS) and Ty21a vaccines have had a World Health Organization (WHO) recommendation for programmatic use in countries with high burden for 10 years, with 1 ViPS vaccine also having WHO prequalification. Despite this, uptake and introduction of these vaccines has been minimal. The development of a controlled human infection model (CHIM) enabled the accelerated testing of the newly WHO-prequalified ViPS-tetanus toxoid protein conjugate vaccine, providing efficacy estimates for the vaccine, prior to larger field trials. There is an urgency to the global control of enteric fever due to the escalating problem of antimicrobial resistance. With more accurate burden of disease estimates and a vaccine showing efficacy in CHIM, that control is now a possibility.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Meiring JE, Giubilini A, Savulescu J, et al. Generating the Evidence for Typhoid Vaccine Introduction: Considerations for Global Disease Burden Estimates and Vaccine Testing Through Human Challenge. Clin Infect Dis. 2019. PMID: 31612941. doi:10.1093/cid/ciz630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。